Back to Search
CHRISTOPHER DAVID CATAPANO DO
DO
Orthopaedic Surgery of the Spine Physician
NPI: 1669732996IndividualAccepts Medicare
Specialties, Licenses & Credentials
Orthopaedic Surgery Physician
Orthopaedic Surgery
Code: 207X00000X
DO2631(NV)
Orthopaedic Surgery of the Spine PhysicianPrimary
Orthopaedic Surgery — Orthopaedic Surgery of the Spine
Code: 207XS0117X
DO2631(NV)
Education
OTHER
Class of 2012
Research & Publications (20)
Promoter-specific transcriptional interference and c-myc gene silencing by siRNAs in human cells.
PMID 19461583·EMBO J·2009
8-other
Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer.
PMID 18037958·Oncogene·2008
4-observational
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.
PMID 18640031·Eur J Cancer·2008
3-trial
Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis.
PMID 18551186·PPAR Res·2008
8-other
Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells.
PMID 18454696·Cancer Biother Radiopharm·2008
8-other
Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.
PMID 17325859·Leuk Lymphoma·2007
8-other
Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma.
PMID 17325905·Leuk Lymphoma·2007
8-other
Block of nuclear receptor ubiquitination. A mechanism of ligand-dependent control of peroxisome proliferator-activated receptor delta activity.
PMID 17324937·J Biol Chem·2007
8-other
Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells.
PMID 16449206·Nucleic Acids Res·2006
8-other
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma.
PMID 16409295·Br J Haematol·2006
8-other
Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.
PMID 16571899·Nucleic Acids Res·2006
8-other
Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas.
PMID 16803564·Br J Haematol·2006
4-observational
Synthesis and anticancer activity of cyclopalladated complexes containing 4-hydroxy-acridine.
PMID 16828871·J Inorg Biochem·2006
8-other
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells.
PMID 17032502·Neoplasia·2006
8-other
Control of peroxisome proliferator-activated receptor fate by the ubiquitinproteasome system.
PMID 17118805·J Recept Signal Transduct Res·2006
6-review
Neomycin improves cationic lipid-mediated transfection of DNA in human cells.
PMID 15950473·Bioorg Med Chem Lett·2005
8-other
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
PMID 15851403·Ann Oncol·2005
8-other
DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene.
PMID 15121897·Nucleic Acids Res·2004
8-other
Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells.
PMID 15314206·Nucleic Acids Res·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 7140 SMOKE RANCH RD STE 150
LAS VEGAS, NV 89128 - Phone
- (702) 320-8111
Quick Facts
- NPI
- 1669732996
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 14
- Publications
- 20
Are you this provider?
Claim Your Profile